阿帕替尼联合口服依托泊苷治疗铂耐药或铂难治性卵巢癌的2期单臂前瞻性研究
该2期单臂前瞻性研究纳入35例铂耐药或铂难治性卵巢癌患者,评估阿帕替尼联合口服依托泊苷的疗效与安全性。
要点
- 阿帕替尼联合口服依托泊苷在铂耐药/难治性卵巢癌中显示 promising 疗效,客观缓解率54%。
- 常见3/4级不良事件包括中性粒细胞减少、乏力、贫血和黏膜炎,毒性可管理。
- 研究支持进一步开展3期临床试验验证该联合方案。
核心结论
- 阿帕替尼联合口服依托泊苷在铂耐药或铂难治性卵巢癌患者中显示出有希望的疗效和可管理的毒性,值得进一步开展3期试验。
研究设计与样本
- 2期、单臂、前瞻性研究,在中国中山大学肿瘤防治中心招募年龄18-70岁的铂耐药或铂难治性卵巢癌患者。
- 治疗方案为阿帕替尼初始剂量500 mg每日一次持续口服,联合口服依托泊苷50 mg每日一次,每21天周期第1-14天给药,依托泊苷最多6个周期。
- 主要终点为根据RECIST 1.1评估的客观缓解比例,采用Simon两阶段设计,在意向治疗和符合方案人群中分析疗效。
主要发现
- 最常见的3或4级不良事件为中性粒细胞减少(17例[50%])、乏力(11例[32%])、贫血(10例[29%])和黏膜炎(8例[24%])。
- 2例患者报告严重不良事件并住院(1例贫血和厌食;另1例因疾病进展腹水增加),未记录治疗相关死亡。
关键数值与推荐
- 客观缓解定义依据RECIST 1.1标准。
- 阿帕替尼初始剂量500 mg每日一次持续给药;口服依托泊苷50 mg每日一次,每21天周期第1-14天,最多6个周期。
临床怎么用
- 对于铂耐药或铂难治性卵巢癌患者,阿帕替尼联合口服依托泊苷可作为一种潜在的口服治疗方案,避免住院给药。
- 治疗期间需重点监测中性粒细胞减少、乏力、贫血和黏膜炎等3/4级不良事件。
局限性
- 本研究为2期单臂研究,无对照组,样本量有限(入组35例)。
- 随访时间较短,数据截止时仅43%患者仍在治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-angiogenic therapy combined with chemotherapy could improve the outcomes of patients with platinum-resistant ovarian cancer. Apatinib is an oral tyrosine kinase inhibitor that selectively inhibits VEGF receptor 2. We assessed the efficacy and safety of the combination therapy of apatinib and oral etoposide, considering the potential advantage of home administration without hospital admission, in patients with platinum-resistant or platinum-refractory ovarian cancer. METHODS: In this phase 2, single-arm, prospective study, we recruited patients aged 18-70 years with platinum-resistant or platinum-refractory ovarian cancer at the Sun Yat-sen University Cancer Center (China). The treatment consisted of apatinib at an initial dose of 500 mg once daily on a continuous basis, and oral etoposide at a dose of 50 mg once daily on days 1-14 of a 21-day cycle. Oral etoposide was administered for a maximum of six cycles. Treatment was continued until disease progression, patient withdrawal, or unacceptable toxic effects. The primary endpoint was the proportion of patients achieving an objective response according to Response Evaluation Criteria in Solid Tumors, version 1.1. We used Simon's two-stage design, and analysed efficacy in the intention-to-treat and per-protocol populations. Safety analyses included enrolled patients who had received at least one dose of study medication, but excluded those without any safety data. This study is registered with ClinicalTrials.gov, number NCT02867956. FINDINGS: Between Aug 10, 2016, and Nov 9, 2017, we screened 38 and enrolled 35 patients. At the data cutoff date (Dec 31, 2017), 20 (57%) patients had discontinued the study, and 15 (43%) patients remained on treatment. Objective responses were achieved in 19 (54%; 95% CI 36·6-71·2) of 35 patients in the intention-to-treat population and in 19 (61%; 42·2-78·2) of 31 patients in the per-protocol population. The most common grade 3 or 4 adverse events were neutropenia (17 [50%]), fatigue (11 [32%]), anaemia (ten [29%]), and mucositis (eight [24%]). Serious adverse events were reported in two patients who were admitted to hospital (one patient had anaemia and anorexia; the other patient had increased ascites due to disease progression). No treatment-related deaths were recorded. INTERPRETATION: The combination of apatinib with oral etoposide shows promising efficacy and manageable toxicities in patients with platinum-resistant or platinum-refractory ovarian cancer, and further study in phase 3 trials is warranted. FUNDING: None.
引用
- Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018. PMID: 30082170. doi:10.1016/S1470-2045(18)30349-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。